

### **Supplementary Table 1.**


Characteristics	No. of CRC patients (%)	No. of HC individuals (%)
Age (years)		
<50	17 (38)	17 (43)
≥50	28 (62)	23 (58)
Gender		
Male	35 (78)	30 (75)
Female	10 (22)	10 (25)
Position		
Colon	18 (40)	
Rectal	27 (60)	
Tumor size		
<2 cm	16 (36)	
≥2 cm	29 (64)	
LNM		
Metastasis	19 (42)	
No metastasis	26 (58)	
Tumor stage		
I+II	27 (60)	
III	18 (40)	

Abbreviations: CRC, Colorectal cancer; HC, Healthy controls; LNM, Lymph node metastasis

Supplementary Table 1. The clinicopathological characteristics of CRC patients








samples. The expression of each miRNA was assessed using CancerMIRNome in CRC.


hs


В




## Supplementary Fig. 1. A. DIANA-miRPATH (TarBase) revealed the most critical pathophysiological features associated with each candidate miRNA. miR-20a-5p exhibited the strongest correlation with most of the proposed features. B. The expression levels of five candidate miRNAs in CRC patients compared to non-tumor








Supplementary Fig. 2. Effects caused by different concentration of  $\alpha$ -amanitin ( $\alpha$ -AMA) on the viability of SW480 CRC cells. Treatment of SW480 cells with increasing concentrations of  $\alpha$ -amanitin (Sigma) for 8 hours demonstrated a dose-dependent reduction in cell survival. These findings were further utilized to determine the IC50 values, which are crucial for subsequent experiments. Notably, at an  $\alpha$ -amanitin concentration of 50  $\mu$ g/mL, the viability of SW480 cells decreased by approximately 50%. Based on these results, the IC50 value of  $\alpha$ -amanitin for SW480 cells was established at 50  $\mu$ g/mL and was subsequently employed in subsequent experimental analyses.




Calnexin

**Supplementary Fig. 3.** Western blots raw data. The full-length blots of Calnexin and CD9. The same membranes were cut and hybridization with different antibodies according to the molecular weights.





CD9





N-cadherin

**Supplementary Fig. 4.** Western blots raw data. The full-length blots of N-cadherin, E-cadherin, Vimentin and β-actin.









**Supplementary Fig. 5.** Western blots raw data. The full-length blots of NF- $\kappa$ B p65 and  $\beta$ -actin.